Share this article on:

Elevated cytokine and chemokine levels in the placenta are associated with in-utero HIV-1 mother-to-child transmission

Kumar, Surender B.a; Rice, Cara E.b; Milner, Danny A. Jrc; Ramirez, Nilsa C.d; Ackerman, William E. IVe; Mwapasa, Victorf; Turner, Abigail Norrisa,g; Kwiek, Jesse J.a,g,h

doi: 10.1097/QAD.0b013e3283519b00
Basic Science

Objective: To determine whether there is an association between cytokine and chemokine levels in plasma isolated from the placenta and HIV-1 mother-to-child transmission (MTCT).

Design: We designed a case–control study of HIV-infected, pregnant women enrolled in the Malaria and HIV in Pregnancy cohort. Participants were recruited in Blantyre, Malawi, from 2000 to 2004. Patients were women whose children were HIV-1 DNA-positive at birth (in-utero MTCT) or HIV-1 DNA-negative at birth and HIV-1 DNA-positive at 6 weeks postpartum (intrapartum MTCT); controls were women whose children were HIV-1 DNA-negative both at birth and 6 weeks postpartum.

Methods: After delivery, blood was isolated from an incision on the basal plate of the placenta. We used a Bio-Plex human cytokine assay (Bio-Rad, Hercules, California USA) to simultaneously quantify 27 cytokines, chemokines and growth factors in placental plasma. HIV-1 RNA copies were quantified with the Roche Amplicor kit.

Results: Levels of interleukin (IL) 4, IL-5, IL-6, IL-7, IL-9, eotaxin, IL-1Ra and interferon gamma-induced protein 10 (IP-10) were significantly elevated in placental plasma isolated from cases of in-utero HIV-1 MTCT. In contrast, only granulocyte colony-stimulating factor was elevated in placental plasma isolated from cases of intrapartum MTCT. After adjusting for maternal age, gestational age and peripheral CD4+ T-cell count, every log10 increase in placental IP-10 was associated with a three-fold increase in the prevalence of in-utero HIV-1 MTCT.

Conclusion: Elevated cytokine and chemokine levels in placental plasma were associated with in-utero and not intrapartum MTCT. IP-10, which is both a T-cell chemokine and potentiator of HIV-replication, was robustly and independently associated with prevalent, in-utero MTCT.

aThe Center for Microbial Interface Biology, The Center for Retrovirus Research

bDivision of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio

cDepartment of Pathology, Brigham & Women's Hospital, Boston, Massachusetts

dDepartment of Pathology and Laboratory Medicine and the Biopathology Center, The Research Institute at Nationwide Children's Hospital, Columbus

eDepartment of Obstetrics and Gynecology, College of Medicine, The Ohio State University, Columbus, Ohio, USA

fDepartment of Community Health, Malawi College of Medicine, Blantyre, Malawi

gDivision of Infectious Diseases, Department of Medicine

hDepartment of Microbial Infection and Immunity and the Department of Microbiology, The Ohio State University, Columbus, Ohio, USA.

Correspondence to Jesse J. Kwiek, 1008 Biomedical Research Tower, 460 West 12th Avenue, Columbus, OH 43210, USA. Tel: +1 614 292 3256; fax: +1 614 292 9616; e-mail:

Received 7 September, 2011

Revised 28 December, 2011

Accepted 19 January, 2012

This research was presented in part at the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, USA (abstract 903).

Back to Top | Article Outline


In populations wherein replacement feeding is unfeasible, it has been estimated that between 25 and 35% of children born to HIV-infected pregnant women will become HIV infected [1]. Of these mother-to-child transmission (MTCT) events, estimates suggest that in a breast-fed population, 25–35% of MTCT occurs in utero prior to delivery, 40–55% during labor and delivery and the remaining 25–35% during breastfeeding [1]. Numerous studies have established that high maternal HIV-1 load is a major risk factor for HIV-1 MTCT [2–6], and reduction of maternal HIV-1 RNA load with antiretroviral drugs significantly reduces the rate of HIV-1 MTCT [7,8]. Additional factors such as chorioamnionitis [9], syphilis [6] and possibly placental inflammation [9–11] have also been associated with HIV-1 MTCT. Although the timing of HIV-transmission is fairly clearly understood, apart from the aforementioned conditions, the molecular mechanism of HIV-1 MTCT is not well understood.

Previous studies from our group indicated that the HIV-1 RNA concentration in placental blood differs by HIV-1 vertical transmission status and that HIV-1 replicates locally in the placental environment [12]; in the same study, we also observed phylogenetic evidence of HIV-1 compartmentalization in placentas isolated from women who transmitted HIV-1 in utero. Viral compartmentalization in the placenta suggests that HIV-1 can adapt to the placental microenvironment. One of the key components that may regulate HIV-1 replication in the placenta is the localized immune state. The maternal–placental interface is a unique immune environment characterized by a strong infiltrate of cells including natural killer cells, macrophages and dendritic cells [13]. These immune cells as well as resident placental cells such as trophoblasts are known to secrete a variety of cytokines, chemokines and growth factors [14]. The influences of these factors on both HIV-1 replication in vivo and HIV-1 MTCT are not fully understood.

Studies on sexual transmission indicate that innate immune defenses play a crucial role in transmission of simian immunodeficiency virus and HIV-1 by compromising the integrity of the vaginal mucosal barrier due to associated inflammation and by increasing target cell availability [15]. A microenvironment facilitating transmission may be created by chemokines [macrophage inflammatory protein (MIP) class] and pro-inflammatory cytokines [granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL) 1, IL-6 and IL-8) that recruit neutrophils, dendritic cells, macrophages and lymphocytes [16,17]. Cytokines also play an important role in the early stages of viral infection by exhibiting direct antiviral activity, activating and recruiting various immune effector cells and modulating adaptive antiviral immune responses [18,19]. Some cytokines and chemokines can upregulate HIV-1 expression in target cells, regulate the availability and activity of transcription factors that bind to the promoter of HIV-1 provirus, enhance expression of target cell receptors and recruit and activate resting CD4+ T lymphocytes [20–25].

Although several groups have addressed the effect of specific cytokine responses in acute HIV-1 infection during sexual transmission [21,26,27], only limited studies have addressed how placental innate immunity may modulate HIV-1 MTCT [28,29]. We designed an exploratory study to interrogate cytokine, chemokine and growth factor levels in placental plasma isolated from 84 HIV-1 nontransmitting, 35 in-utero and 34 intrapartum transmitting mothers. The overall objective of this study is to determine whether immune modulation in the placental milieu is associated with HIV-1 MTCT.

Back to Top | Article Outline

Patients and methods

Study participants and clinical isolates

All participants gave written, informed consent to participate. Ethical approval for the parent Malaria and HIV in Pregnancy (MHP) observational cohort was obtained from the University of North Carolina at Chapel Hill Institutional Review Board and the Malawi College of Medicine Research Ethics Board; approval for the present case–control study, which used only de-identified information, was obtained from the Ohio State University. Blood samples were collected as part of the MHP cohort, which enrolled 3824 pregnant women admitted to the Labor and Delivery ward of Queen Elizabeth Central Hospital in Blantyre, Malawi, from 2001 to 2004 [6,30]. Women were ineligible for MHP if they were in the active phase of labor, were participating in other research studies, were less than 15 years of age, had hypertension, multiple gestations or altered consciousness. Maternal HIV-1 status was determined by two rapid tests, as described previously [30]. Pregnant women with acute HIV infection [31] were excluded from this study. Women who delivered stillbirths or died at delivery were also excluded from the study. At the onset of active labor, women received a single dose of nevirapine and shortly after birth, infants received a single dose of nevirapine, both according to the HIVNET 012 protocol [8]. Infant HIV-1 status was determined by real-time PCR testing according to the methods of Luo et al. [32], and pediatric HIV infection was categorized according to standard definitions [33], as follows: HIV-1 transmission cases were classified as in-utero transmissions if infants were HIV-1 DNA positive within 48 h of birth, as intrapartum transmissions if infants were HIV-1 DNA negative at birth and HIV-1 DNA positive 6 weeks postpartum and as HIV-1 negative, or nontransmitters, if infant samples from both birth and 6 weeks postpartum were HIV-1 DNA negative. Overall, 1157 (30%) of the pregnant women in MHP were HIV-1 infected, with 73 (9%) of their newborns HIV-1 infected in utero and 66 (13%) infected intrapartum [6]. Maternal hemoglobin concentration was determined by Hemocue hemoglobinometer (HemoCue AB, Ängelholm, Sweden); CD4+ T cells were quantified by FACScan (Becton Dickinson, San Jose, California, USA); HIV-1 RNA was quantified from peripheral and placental plasma using Amplicor HIV-1 Monitor v1.5 (Roche Diagnostics, Branchburg, New Jersey, USA), with plasma HIV-1 RNA concentrations less than 400 assigned a value of 400 copies/ml. Peripheral malaria was diagnosed using Geimsa-stained thick and thin blood smears and placental malaria was diagnosed based on placental histology, both as described in Mwapasa et al. [30]. Syphilis was diagnosed using the rapid plasma reagin test (RPR; Omega Diagnostics, Alloa, Scotland), and all RPR reactive sera were tested with the Treponema pallidum hemagglutination assay (TPHA; Omega Diagnostics). Participants with a reactive RPR followed by a reactive TPHA were considered syphilis seroreactive, as described [34].

Back to Top | Article Outline

Study design

Placental plasma was available from 35 women whose infants became HIV-infected in utero and 34 women whose infants became infected intrapartum. Owing to the exploratory nature of the study, the number of nontransmitter samples in the control group was selected based on the number of assays available per 96-well plate (n = 84). The 84 nontransmitter samples were randomly chosen, using STATA (version 10.1; StataCorp., College Station, Texas, USA), from the total collection of nontransmitter samples with placental plasma available. By design, nontransmitter samples were not matched with either in-utero or intrapartum samples. The participants included in this study were similar to those not included with regard to maternal age, CD4+ T-cell count and peripheral HIV-1 concentration (Wilcoxon rank–sum test, all P values greater than 0.3). When stratified by HIV-transmission status (nontransmitter, in utero, intrapartum), included and excluded participants were also similar, with the exception of peripheral viral load in the in-utero subgroup: the included in-utero samples had a lower peripheral viral load than those not included (4.7 vs. 5.1 log10 copies/ml, Wilcoxon rank sum test, P = 0.08).

Back to Top | Article Outline

Collection of placental plasma

After delivery of the placenta, an incision was made in the middle of the maternal surface of the placenta, 2-cm long and through half the thickness of the placental tissue. The placental blood that pooled in the incision was collected, and plasma was prepared according to standard protocols.

Back to Top | Article Outline

Luminex cytokine assay

Twenty-seven analytes were simultaneously quantified from 20 μl of placental plasma with a Bio-Plex Pro Human Cytokine 27-plex kit (BioRad, Hercules, California, USA) according to the manufacturer's instructions. The analytes include the following: IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, eotaxin, fibroblast growth factor (FGF) basic, granulocyte colony-stimulating factor (G-CSF), GM-CSF, interferon (IFN)-γ, interferon gamma-induced protein (IP) 10, monocyte chemoattractant protein 1, MIP-1α, MIP-1β, platelet-derived growth factor (PDGF)-BB, RANTES (Regulated upon Activation, Normal T-cell Expressed, and Secreted), tumor necrosis factor α and vascular endothelial growth factor (VEGF). Data were acquired using a Bio-Plex-200 suspension array system and the cytokine/chemokine concentrations were automatically calculated with Bio-Plex Manager software 5.0 using a standard curve derived from a recombinant cytokine standard (supplied by the manufacturer). When a limited number of the data were outside of the range of the standard curve, the values were set to the maximum or minimum value of the standard curve. The majority of the FGF basic, MIP-1α, VEGF and RANTES data were outside of the range of the standard curve and, therefore, were excluded from further analysis.

Back to Top | Article Outline

Evaluation of placental biopsies

A subset of the participants had representative formalin-fixed, paraffin-embedded full-thickness placental biopsies available. Routine tissue sections were cut from placental biopsies and stained with hematoxylin and eosin (H&E), according to standard protocols. Histopathological analysis of placental sections was performed by an expert placental pathologist (N.C.R.). Light microscopy evaluation was performed using standard objectives (4×, 10×, 20× and 40×). The presence or absence of histological placental parenchymal abnormalities was noted, including edema, increased syncytial knots, changes in the villous vasculature, placental maturity and nonspecific acute and/or chronic villitis and/or intervillositis. Histological evidence of infection with the ToRCHES microbes (Toxoplasma, Rubella, Cytomegalovirus, Herpes, Enteroviruses, and Syphilis), which are known to cross the maternal–fetal barrier, was also assessed. Chorioamnionitis was assessed by a single pathologist (D.A.M.) according to methods previously described [35]. Briefly, H&E stained sections of cord, membranes and placenta and/or Giemsa-stained sections of placenta were evaluated under light microscopy for the presence of neutrophils in the chorion, amnion, umbilical cord and fetal plate. Both pathologists were masked to the HIV-1 transmission status of the participants.

Back to Top | Article Outline

Statistical analysis

Statistical analysis was performed with STATA and SAS (version 9.2, Cary, North Carolina, USA). The Wilcoxon rank–sum test or the Fisher's exact test was used to compare clinical and virological features between the transmission groups. Univariate associations were tested with a two-sample Wilcoxon rank–sum test, with in utero and intrapartum considered as separate outcomes. As this is an exploratory study, we did not correct for multiple hypothesis testing [36], except as a sensitivity analysis of our main findings. In that case, we applied a Bonferroni correction (P value cutoff = 0.05 divided by 23 analytes equals an adjusted P value cutoff of 0.002). To further explore the association between IP-10 and in-utero MTCT, we used regression models specifying the Poisson distribution, with IP-10 as the primary exposure and transmission status (in utero vs. nontransmitters) as the outcome; intrapartum transmission events were excluded from the multivariable modeling analyses. All cytokine measures were log10 transformed prior to modeling. The exposure variable and all covariates met the assumption of linearity in the log risk. On the basis of previous literature and preliminary analysis, we assessed maternal age, gestational age, CD4+ T-cell count, hemoglobin level, maternal temperature at delivery, IL-4, IL-5, IL-6, IL-7, IL-9, eotaxin and IL-1Ra as potential confounders. The full model was reduced using manual backward elimination [37]. We assessed potential confounders one by one and retained those variables that changed the main effect estimate by more than 10% when removed from the full model.

Back to Top | Article Outline


Participant characteristics

We designed a case–control study to compare the concentration, in placental blood, of several chemokines, cytokines and growth factors stratified by HIV-1 MTCT status. In total, 153 placental plasma isolates were included in the analysis: 35 from cases of in-utero transmission (in-utero MTCT), 34 from cases of intrapartum transmission (intrapartum MTCT) and 84 from cases of HIV-exposed but uninfected (nontransmitters). The three groups were balanced for most maternal characteristics, with the exception of gestational age (slightly lower among cases of in-utero MTCT) and both peripheral and placental viral load (higher among both in-utero and intrapartum MTCT cases) (Table 1).

Table 1

Table 1

Back to Top | Article Outline

Multiple cytokines and chemokines are associated with in-utero HIV-1 mother-to-child transmission

The primary objective of this study was to compare analyte levels in placental blood isolated from mother–infant pairs with known HIV-transmission status (Table 2). Median analyte levels in each of the transmission categories were consistent with previously published range of analyte concentrations [27]. Owing to the likelihood that in-utero and intrapartum MTCT occur via different biological mechanisms, we analyzed the data as two separate case–control studies, nontransmitters vs. in utero and nontransmitters vs. intrapartum. Eight analytes in placental blood were significantly higher in cases of in-utero transmission compared with nontransmitters (Table 2 and Fig. 1): IL-4 (36%), IL-5 (200%), IL-6 (56%), IL-7 (35%), IL-9 (218%), eotaxin (162%), IL-1Ra (190%) and IP-10 (252%). In contrast, only G-CSF was elevated during intrapartum MTCT, by 159%. After correcting for multiple comparisons, only the association between IP-10 and in-utero MTCT remained statistically significant. These data suggest that the placental environment, specifically the cytokines and chemokines present in the placenta, differs by both HIV-1 transmission status and by mode of transmission.

Table 2

Table 2

Fig. 1

Fig. 1

We examined a matrix of correlation coefficients to evaluate the association between CD4+ T-cell count, HIV-1 RNA concentration and the chemokines and cytokines that were associated with in-utero MTCT (Table 3). Although several of the analytes were strongly correlated with each other, none was strongly or significantly associated with CD4+ T-cell count. IP-10 was significantly yet weakly correlated with peripheral HIV-1 RNA level and strongly correlated with placental HIV-1 RNA level. Participants with placental malaria had higher levels of IP-10 in placental plasma than participants without evidence of placental malaria (2.4 vs. 2.7 log10 pg/ml IP-10, P = 0.05, Wilcoxon rank–sum test). Previous studies have documented an association between IP-10 levels in amniotic fluid and chorioamnionitis, but we observed no correlation between IP-10 concentration in placental plasma and chorioamnionitis (P = 0.3, two-sample Wilcoxon rank–sum test).

Table 3

Table 3

Back to Top | Article Outline

Placental histology

In order to exclude microbial infection of the placenta, we analyzed placental biopsies for evidence of histological abnormalities. A total of 94 biopsies were available for analysis: 56 of 84 nontransmitters (67%), 17 of 35 in utero (49%) and 21 of 34 intrapartum (62%). This subset of placental biopsies was a convenience sample and did not differ from the parent population in regard to peripheral HIV-1 concentration, CD4+ T-cell count, gestational age, maternal age, IL-4, IP-10 or IFN-γ levels (data not shown). We observed no significant microscopic placental pathological findings associated with in-utero MTCT, including those traditionally associated with malaria or ToRCHES infections. However, edema, either in the placenta or in the fetal membranes, was observed in 10 nontransmitters (20%), six in-utero (38%) and 10 intrapartum (50%) biopsies (nontransmitters vs. in utero, P = 0.2; nontransmitters vs. intrapartum, P = 0.02; Fisher's exact test). We identified several curious findings, including a less-than-typical amount of fibrin in the intervillous space and a high prevalence of syncytial knots, although neither feature was associated with HIV-1 transmission (data not shown).

Back to Top | Article Outline

Regression analysis

Our preliminary analyses suggested that IP-10 may be meaningfully associated with in-utero MTCT. In a univariate Poisson regression analysis, every log10 increase in IP-10 increased the prevalence of in-utero MTCT by 70% [prevalence ratio: 1.7, 95% confidence interval (CI): 1.3–2.3]. We built a multivariate Poisson regression model with in-utero MTCT as the dependent variable, IP-10 as the primary exposure variable of interest and all covariates found to be significant in univariate analyses as potentially confounding variables. After backward elimination, gestational age, IL-4, IL-5, IL-7 and IL-1Ra were retained as confounders (Table 4). Maternal age and CD4+ T-cell count were kept in the final regression model for a priori considerations even though they did not meet the 10% criterion for confounding. The remaining variables (temperature, hemoglobin, IL-6, IL-9 and eotaxin) were not retained. After adjustment, every log10 increase in IP-10 increased the prevalence of in-utero MTCT more than three-fold (prevalence ratio: 3.3, 95% CI: 1.3–8.1). We conducted two sensitivity analyses: one including placental viral load in place of CD4+ T-cell count in the final model and the other including peripheral viral load in place of CD4+ T-cell count in the final model (models containing CD4+ T-cell count together with either viral load variable did not converge due to collinearity.) Both viral load variables had considerable missing data, leading to a loss of 37 and 12% of patients, respectively, when placental or peripheral viral load were used in place of CD4+ T-cell count. For the model containing placental viral load, the prevalence ratio for IP-10 was similar to the primary analysis (prevalence ratio: 3.6, 95% CI: 1.0–13). For the model containing peripheral viral load, the prevalence ratio for in-utero MTCT was again similar at 3.7 (95% CI: 1.2–11). Both sensitivity analyses indicated that use of CD4+ T-cell count instead of viral load did not meaningfully change the magnitude of the observed effect of IP-10 on in-utero MTCT, though precision of the estimate after adjustment for viral load suffered because of missing data leading to smaller sample size.

Table 4

Table 4

Back to Top | Article Outline


The objective of this exploratory case–control study was to determine whether the levels of chemokines, cytokines or growth factors in placental plasma were associated with HIV-1 MTCT. We observed the following: IL-4, IL-5, IL-6, IL-7, IL-9, eotaxin, IL-1Ra and IP-10 levels and HIV-1 RNA concentration were higher in placental plasma from in-utero MTCT than in placental plasma from nontransmitter controls, only G-CSF was elevated in placental plasma prepared from intrapartum MTCT cases compared with placental plasma from nontransmitter controls and after adjustment for confounding variables and either CD4+ T-cell number or viral load, multivariate modeling indicated that IP-10 levels were independently associated with a three-fold increase in the prevalence of in-utero MTCT. These observations suggest that an altered immune environment in the placenta is associated with in-utero MTCT and not intrapartum MTCT.

Many of the analytes elevated in placental plasma during in-utero MTCT have previously been associated with HIV-1 infection. For example, IL-1Ra, an inducible receptor antagonist of IL-1, is known to be elevated in inflammatory diseases, including HIV-1, in which it may serve as a marker of disease progression [38–41]. Increased levels of IL-7 is consistent with other studies; however, these studies also found increased IL-7 in correlation with the level of CD4+ T-cell depletion, suggesting the role of IL-7 in T-cell apoptosis and hence disease progression [42–44]. However, a similar association between IL-7 and CD4+ T-cell count was not observed in these samples (Table 3). IL-6 is considered a pro-inflammatory mediator and has been shown to induce HIV-1 replication by both transcriptional and posttranscriptional mechanisms [45]. On the contrary, HIV-1 infection is also known to induce IL-6 [46,47], which confounds our ability to interpret the association between in-utero MTCT, IL-6 and HIV-1 RNA concentration in placental blood. IL-4 is an important regulator and marker of accelerated HIV-1 disease progression and has been shown to collaborate with HIV-1 to induce IL-6 production, thereby resulting in global B-cell dysfunction [48,49]. Finally, IL-5 and eotaxin can both recruit eosinophils, which have been shown to be permissive targets for HIV-1 replication [50,51].

The observed changes in multiple placental cytokine/chemokine profiles during in-utero MTCT is in stark contrast to the placental cytokine/chemokine profile during intrapartum MTCT, in which only G-CSF level was elevated. The observed contrast in cytokine levels between in-utero and intrapartum MTCT provides additional data to support the hypothesis that in-utero and intrapartum MTCT have different molecular mechanisms. Consistent with this hypothesis, we (and others) have previously observed no association between maternal-fetal blood admixture (also called placental microtransfusions) and in-utero MTCT [52–54]; in contrast, using two different assays, we have observed an association between placental microtransfusions and intrapartum MTCT [52,53]. Whether or not the prevalent edema that was associated with intrapartum MTCT is related to placental microtransfusions cannot be determined from this study.

IP-10, also called CXCL10, is a type 1 chemokine that binds to the CXCR3 receptor [55] and attracts Th1 lymphocytes, monocytes, eosinophils and dendritic cells, many of which are permissive to HIV-1 infection and replication. In this study, IP-10 was significantly correlated with peripheral and placental HIV-1 RNA concentration, and IP-10 levels were independently correlated with in-utero MTCT. IP-10 has been shown to increase HIV-1BAL replication in monocyte-derived macrophages and peripheral blood lymphocytes [56], which could explain the elevated HIV-1 RNA concentration in placentas obtained from in-utero MTCT cases; to our knowledge, data demonstrating a direct affect of IP-10 on HIV-1 replication in the placental microenvironment has not been reported. Given the sequence variability within in the HIV-1 promoter [57], further studies are needed to determine whether all HIV-1 variants replicate similarly when IP-10 signaling cascades are activated. Other studies have shown that IP-10 levels in peripheral blood are transiently induced during the acute stage of HIV-1 infection [27] and during untreated, progressive HIV-1 infection [58]. Malaria infection has been associated with both increased levels of IP-10 [59,60] and leukocyte infiltration into the placenta [61,62], each of which could potentially create an environment favoring HIV-1 replication. In this study, we observed a small yet significant association between placental malaria and placental IP-10 levels; as we have previously reported in the parent MHP cohort, placental malaria was associated with an increased HIV-1 concentration in the placenta [30], but it was not associated with an increased prevalence of HIV-1 MTCT [6].

Multiple cell types secrete IP-10, including keratinocytes, endothelial cells, macrophages and fibroblasts in the adult [63] and Hofbauer cells, stromal cells and endothelial cells on the fetal side of the maternal–fetal interface [64]. Preterm infants can have transiently elevated IP-10 levels [65]. Although we interpret cytokine and chemokine levels in placental blood to reflect their concentration in maternal blood in the intervillous space, it is also possible that the method of blood collection used in this study (incision) created maternal–fetal blood admixture [66]. Only by repeating the cytokine/chemokine arrays on umbilical cord blood could we conclusively determine whether the data reflect the cytokine storm in the fetus. Unfortunately, this type of specimen is not available from this study. Several observations from our previous study [12], which used samples from the same cohort obtained using the same method of placental blood collection, argue against placental blood representing only fetal blood. First, we sequenced HIV-1 envelope genes from peripheral blood, placental blood and umbilical cord blood, and the collection of env genes in both maternal and placental blood were highly diverse, in stark contrast to the nearly homogenous viral population in cord blood. If the placental blood only represented fetal blood, we would expect it to have minimal viral sequence diversity. Second, phylogenetic reconstruction identified a fetal compartment of HIV-1 that was distinct from the placental compartment [12]. However, even if our findings reflect the cytokine/chemokine profile following acute fetal HIV-infection, they are consistent with a previous report of elevated plasma IP-10 in plasma donors acutely infected with HIV-1 [27].

In summary, this study supports the association between elevated levels of specific cytokines and chemokines in placental plasma and in-utero, but not intrapartum, MTCT. IP-10 levels were independently associated with in-utero MTCT, and this association remained after controlling for maternal immune status and other confounding variables. These data may provide a direct link between the placental immunological state and viral replication, either through direct enhancement of HIV-1 transcription or via localized recruitment of cells that are permissive to HIV-replication.

Back to Top | Article Outline


We are grateful for the participation of the Malawian women and their newborns. We thank the Malaria and HIV in Pregnancy Cohort staff and Drs Steven Meshnick and Stephen Rogerson for designing and managing the MHP cohort (R01-AI49084).

All authors contributed to data collection, analysis and manuscript editing. S.B.K. and J.J.K. wrote the first draft of the manuscript.

This research was supported in part by NIH grants K99/R00HD056586 to J.J.K. The content of this article is solely the responsibility of the authors and it does not necessarily represent the official views of the NIH.

Back to Top | Article Outline

Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline


1. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000; 283:1175–1182.
2. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484–494.
3. John GC, Nduati RW, Mbori-Ngacha DA, Richardson BA, Panteleeff D, Mwatha A, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183:206–212.
4. Montano M, Russell M, Gilbert P, Thior I, Lockman S, Shapiro R, et al. Comparative prediction of perinatal human immunodeficiency virus type 1 transmission, using multiple virus load markers. J Infect Dis 2003; 188:406–413.
5. The European Collaborative Study: maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 1999; 13:1377–1385.
6. Mwapasa V, Rogerson SJ, Kwiek JJ, Wilson PE, Milner D, Molyneux ME, et al. Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. AIDS 2006; 20:1869–1877.
7. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173–1180.
8. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795–802.
9. Goldenberg RL, Vermund SH, Goepfert AR, Andrews WW. Choriodecidual inflammation: a potentially preventable cause of perinatal HIV-1 transmission?. Lancet 1998; 352:1927–1930.
10. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, Serwadda D, Sewankambo N, Lutalo T, et al. The effects of placental malaria on mother-to-child HIV transmission in Rakai, Uganda. AIDS 2003; 17:2539–2541.
11. Mwanyumba F, Gaillard P, Inion I, Verhofstede C, Claeys P, Chohan V, et al. Placental inflammation and perinatal transmission of HIV-1. J Acquir Immune Defic Syndr 2002; 29:262–269.
12. Kumar SB, Handelman SK, Voronkin I, Mwapasa V, Janies D, Rogerson SJ, et al. Different regions of HIV-1 subtype C env are associated with placental localization and in utero mother-to-child transmission. J Virol 2011; 85:7142–7152.
13. Gomez-Lopez N, Guilbert LJ, Olson DM. Invasion of the leukocytes into the fetal-maternal interface during pregnancy. J Leukoc Biol 2010; 88:625–633.
14. Guilbert L, Robertson SA, Wegmann TG. The trophoblast as an integral component of a macrophage-cytokine network. Immunol Cell Biol 1993; 71 (Pt 1):49–57.
15. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464:217–223.
16. Berlier W, Cremel M, Hamzeh H, Levy R, Lucht F, Bourlet T, et al. Seminal plasma promotes the attraction of Langerhans cells via the secretion of CCL20 by vaginal epithelial cells: involvement in the sexual transmission of HIV. Hum Reprod 2006; 21:1135–1142.
17. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458:1034–1038.
18. Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 2005; 79:12164–12172.
19. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657–700.
20. Chehimi J, Luo Q, Azzoni L, Shawver L, Ngoubilly N, June R, et al. HIV-1 transmission and cytokine-induced expression of DC-SIGN in human monocyte-derived macrophages. J Leukoc Biol 2003; 74:757–763.
21. Esser R, Glienke W, von Briesen H, Rubsamen-Waigmann H, Andreesen R. Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus. Blood 1996; 88:3474–3481.
22. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987; 238:800–802.
23. Koyanagi Y, O’Brien WA, Zhao JQ, Golde DW, Gasson JC, Chen IS. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 1988; 241:1673–1675.
24. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987; 326:711–713.
25. Swingler S, Mann A, Jacque J, Brichacek B, Sasseville VG, Williams K, et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med 1999; 5:997–1103.
26. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, Busch MP. Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses 2006; 22:757–762.
27. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83:3719–3733.
28. Derrien M, Faye A, Dolcini G, Chaouat G, Barre-Sinoussi F, Menu E. Impact of the placental cytokine-chemokine balance on regulation of cell-cell contact-induced human immunodeficiency virus type 1 translocation across a trophoblastic barrier in vitro. J Virol 2005; 79:12304–12310.
29. Zachar V, Fink T, Koppelhus U, Ebbesen P. Role of placental cytokines in transcriptional modulation of HIV type 1 in the isolated villous trophoblast. AIDS Res Hum Retroviruses 2002; 18:839–847.
30. Mwapasa V, Rogerson SJ, Molyneux ME, Abrams ET, Kamwendo DD, Lema VM, et al. The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women. AIDS 2004; 18:1051–1059.
31. Gay CL, Mwapasa V, Murdoch DM, Kwiek JJ, Fiscus SA, Meshnick SR, et al. Acute HIV infection among pregnant women in Malawi. Diagn Microbiol Infect Dis 2010; 66:356–360.
32. Luo W, Yang H, Rathbun K, Pau C-P, Ou C-Y. Detection of HIV-1 DNA in dried blood spots using a duplex real-time PCR assay. J Clin Microbiol 2005; 43:1851–1857.
33. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992; 327:1246–1247.
34. Kwiek JJ, Mwapasa V, Alker AP, Muula AS, Misiri HE, Molyneux ME, et al. Socio-demographic characteristics associated with HIV and syphilis seroreactivity among pregnant women in Blantyre, Malawi, 2000–2004. Malawi Med J 2008; 20:80–85.
35. Abrams ET, Milner DA Jr, Kwiek J, Mwapasa V, Kamwendo DD, Zeng D, et al. Risk factors and mechanisms of preterm delivery in Malawi. Am J Reprod Immunol 2004; 52:174–183.
36. Bender R, Lange S. Adjusting for multiple testing: when and how?. J Clin Epidemiol 2001; 54:343–349.
37. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138:923–936.
38. de Rochemonteix-Galve B, Dayer JM, Junod AF. Fibroblast–alveolar cell interactions in sarcoidosis and idiopathic pulmonary fibrosis: evidence for stimulatory and inhibitory cytokine production by alveolar cells. Eur Respir J 1990; 3:653–664.
39. Kreuzer KA, Dayer JM, Rockstroh JK, Sauerbruch T, Spengler U. The IL-1 system in HIV infection: peripheral concentrations of IL-1beta, IL-1 receptor antagonist and soluble IL-1 receptor type II. Clin Exp Immunol 1997; 109:54–58.
40. Seckinger P, Williamson K, Balavoine JF, Mach B, Mazzei G, Shaw A, et al. A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J Immunol 1987; 139:1541–1545.
41. Zarate S, Pond SL, Shapshak P, Frost SD. Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1. J Virol 2007; 81:6643–6651.
42. Llano A, Barretina J, Gutierrez A, Blanco J, Cabrera C, Clotet B, et al. Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. J Virol 2001; 75:10319–10325.
43. Mastroianni CM, Forcina G, d’Ettorre G, Lichtner M, Mengoni F, D’Agostino C, et al. Circulating levels of interleukin-7 in antiretroviral-naive and highly active antiretroviral therapy-treated HIV-infected patients. HIV Clin Trials 2001; 2:108–112.
44. Sasson SC, Zaunders JJ, Zanetti G, King EM, Merlin KM, Smith DE, et al. Increased plasma interleukin-7 level correlates with decreased CD127 and Increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infection. J Infect Dis 2006; 193:505–514.
45. Poli G, Bressler P, Kinter A, Duh E, Timmer WC, Rabson A, et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and posttranscriptional mechanisms. J Exp Med 1990; 172:151–158.
46. Ambrosino C, Ruocco MR, Chen X, Mallardo M, Baudi F, Trematerra S, et al. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem 1997; 272:14883–14892.
47. Shah A, Verma AS, Patel KH, Noel R, Rivera-Amill V, Silverstein PS, et al. HIV-1 gp120 induces expression of IL-6 through a nuclear factor-kappa B-dependent mechanism: suppression by gp120 specific small interfering RNA. PLoS One 2011; 6:e21261.
48. Boue F, Wallon C, Goujard C, Barre-Sinoussi F, Galanaud P, Delfraissy JF. HIV induces IL-6 production by human B lymphocytes. Role of IL-4. J Immunol 1992; 148:3761–3767.
49. Valentin A, Lu W, Rosati M, Schneider R, Albert J, Karlsson A, et al. Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression. Proc Natl Acad Sci U S A 1998; 95:8886–8891.
50. Rothenberg ME, Ownbey R, Mehlhop PD, Loiselle PM, van de Rijn M, Bonventre JV, et al. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol Med 1996; 2:334–348.
51. Weller PF, Marshall WL, Lucey DR, Rand TH, Dvorak AM, Finberg RW. Infection, apoptosis, and killing of mature human eosinophils by human immunodeficiency virus-1. Am J Respir Cell Mol Biol 1995; 13:610–620.
52. Kwiek JJ, Mwapasa V, Milner DAJ, Alker AP, Miller WC, Tadesse E, et al. Maternal–fetal microtransfusions and HIV-1 mother-to-child transmission in Malawi. PLoS Med 2006; 3:e10.
53. Kwiek JJ, Arney LA, Harawa V, Pedersen B, Mwapasa V, Rogerson SJ, et al. Maternal-fetal DNA admixture is associated with intrapartum mother-to-child transmission of HIV-1 in Blantyre, Malawi. J Infect Dis 2008; 197:1378–1381.
54. Lee TH, Chafets DM, Biggar RJ, McCune JM, Busch MP. The role of transplacental microtransfusions of maternal lymphocytes in in utero HIV transmission. J Acquir Immune Defic Syndr 2010; 55:143–147.
55. Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 2011; 22:121–130.
56. Lane BR, King SR, Bock PJ, Strieter RM, Coffey MJ, Markovitz DM. The C-X-C chemokine IP-10 stimulates HIV-1 replication. Virology 2003; 307:122–134.
57. Krebs FC, Mehrens D, Pomeroy S, Goodenow MM, Wigdahl B. Human immunodeficiency virus type 1 long terminal repeat quasispecies differ in basal transcription and nuclear factor recruitment in human glial cells and lymphocytes. J Biomed Sci 1998; 5:31–44.
58. Keating SM, Golub ET, Nowicki M, Young M, Anastos K, Crystal H, et al. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of US women. AIDS 2011, 25:1823–1832.
59. Chaisavaneeyakorn S, Moore JM, Othoro C, Otieno J, Chaiyaroj SC, Shi YP, et al. Immunity to placental malaria. IV. Placental malaria is associated with up-regulation of macrophage migration inhibitory factor in intervillous blood. J Infect Dis 2002; 186:1371–1375.
60. Suguitan ALJ, Leke RG, Fouda G, Zhou A, Thuita L, Metenou S, et al. Changes in the levels of chemokines and cytokines in the placentas of women with Plasmodium falciparum malaria. J Infect Dis 2003; 188:1074–1082.
61. Leopardi O, Naughten W, Salvia L, Colecchia M, Matteelli A, Zucchi A, et al. Malaric placentas. A quantitative study and clinico-pathological correlations. Pathol Res Pract 1996; 192:892–898.discussion 899–900.
62. Rogerson SJ, Pollina E, Getachew A, Tadesse E, Lema VM, Molyneux ME. Placental monocyte infiltrates in response to Plasmodium falciparum malaria infection and their association with adverse pregnancy outcomes. Am J Trop Med Hyg 2003; 68:115–119.
63. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61:246–257.
64. Kim MJ, Romero R, Kim CJ, Tarca AL, Chhauy S, LaJeunesse C, et al. Villitis of unknown etiology is associated with a distinct pattern of chemokine up-regulation in the feto-maternal and placental compartments: implications for conjoint maternal allograft rejection and maternal antifetal graft-versus-host disease. J Immunol 2009; 182:3919–3927.
65. Kinjo T, Ohga S, Ochiai M, Honjo S, Tanaka T, Takahata Y, et al. Serum chemokine levels and developmental outcome in preterm infants. Early Hum Dev 2011; 87:439–443.
66. Othoro C, Moore JM, Wannemuehler K, Nahlen BL, Otieno J, Slutsker L, et al. Evaluation of various methods of maternal placental blood collection for immunology studies. Clin Vaccine Immunol 2006; 13:568–574.

chemokines; HIV-1; interferon gamma-induced protein 10; mother-to-child transmission; placenta; sub-Saharan Africa

© 2012 Lippincott Williams & Wilkins, Inc.